Inhibrx Biosciences, Inc. (INBX)
- Sector
- Biotechnology
- Last price
- $87.08
- As of
Kresmion compiles this page from INBX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Inhibrx Biosciences, Inc. (INBX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
See the full INBX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INBX on one page. Preview it with sample data, then open it live with a free account.
Preview the INBX dossierActive signals for INBX
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 96% of INBX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 73% of INBX (2026Q2)
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in INBX
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 55% of INBX (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +245% to INBX (2026Q2)
FREE, NO ACCOUNT
Every signal on INBX, as it fires
You are seeing 5 of 11 signals recorded on INBX since 2026-05-27.
The five above all landed on 2026-08-16. The other 6 were recorded on 2 other days. 8 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INBX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 45720N103 · 2026Q2 | $106.5M | 0.30% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45720N103 · 2026Q2 | $13.9M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45720N103 · 2026Q2 | $5.9M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 45720N103 · 2026Q2 | $2.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45720N103 · 2026Q2 | $2.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INBX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INBX against its peers
INBX's operating margin of -10386.5% ranks in the 5th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | INBX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.3M USD | 178M USD | 6 | 8 |
| Operating margin | -10386.5% | -79.5% | 5 | 9 |
| Net margin | -10773.5% | -78.3% | 5 | 9 |
| Return on equity | -1752.2% | -36.9% | 3 | 15 |
| 1 year | 153.3% | -11.1% | 90 | 14 |
Peers (19): TYRA, ANAB, DRTS, DMRA, GHRS, RAPP, ORIC, MAZE, TSHA, IMCR, RARE, NBTX, SNDX, LBRX, CMPS, QURE, VOR, REPL, STOK. Left out: AAPG (period gap), KARD (no annual filing), COAG (no annual filing), KALV (no annual filing), KLRA (no annual filing), TRAX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (INBX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INBX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INBX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.